Australia · Delayed Price · Currency is AUD Ansell Earnings Call Transcripts
Fiscal Year 2026
-
Double-digit adjusted EPS growth and record cash flow were achieved despite subdued markets, with tariff costs fully offset by price increases and productivity gains. Guidance is maintained, supported by innovation, strong balance sheet, and ongoing share buybacks.
Fiscal Year 2025
-
Strong FY2025 results were driven by organic growth, successful KBU integration, and productivity gains. The board addressed U.S. tariff risks, labor rights, and sustainability, with ongoing board succession and digital transformation initiatives.
-
Delivered strong FY 2025 results with 8% organic sales growth, 10% EBIT growth, and adjusted EPS at the top end of guidance. KBU integration exceeded expectations, and a $200M share buyback is planned. FY 2026 guidance anticipates further growth and tariff mitigation.
-
Double-digit growth in both revenue and profit, driven by strong Healthcare and Industrial segments, successful KBU integration, and productivity gains. EPS guidance was raised, with cost and supply chain risks managed through pricing and operational flexibility.
Fiscal Year 2024
-
The meeting reviewed FY24 results, with industrial growth offsetting healthcare declines and strong cash conversion. Strategic highlights included the Kimberly-Clark PPE acquisition, APIP progress, and advanced sustainability initiatives. Shareholders engaged on governance, capital raising, and legal matters.
-
Adjusted EPS landed near the top of guidance, driven by record industrial margins and strong cash flow, while healthcare recovered as destocking eased. The KBU acquisition is integrating well, with modest FY25 EPS impact expected, and sustainability leadership was recognized by top agencies.